Advertisement
Screener

Viridian Therapeutics, Inc./DE (VRDN) Revenue, Net (Deprecated 2018-01-31)

2.0 / 5 stars · 36/91 Roast Me

Viridian Therapeutics, Inc./DE Revenue, Net (Deprecated 2018-01-31)

Viridian Therapeutics, Inc./DE (VRDN) reported Revenue, Net (Deprecated 2018-01-31) of $4.78 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.

Discontinued › Income Statement › Revenue

us-gaap:SalesRevenueNet · last filed 2018-05-09

  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.78M, a 935.50% increase year-over-year.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.19M, a 134.18% increase year-over-year.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.63M, a 74.25% increase year-over-year.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $718.00K, a 35.61% decline year-over-year.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for fiscal 2017 was $4.00M, a 15.13% increase from fiscal 2016.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for fiscal 2016 was $3.48M, a 37.00% increase from fiscal 2015.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for fiscal 2015 was $2.54M, a 41.25% decline from fiscal 2014.
  • Viridian Therapeutics, Inc./DE revenue, net (deprecated 2018-01-31) for fiscal 2014 was $4.32M, a 0.09% increase from fiscal 2013.
Period endRevenue, Net (Deprecated 2018-01-31) 3 monthRevenue, Net (Deprecated 2018-01-31) 3 month as first filedRevenue, Net (Deprecated 2018-01-31) 6 monthRevenue, Net (Deprecated 2018-01-31) 6 month as first filedRevenue, Net (Deprecated 2018-01-31) 9 monthRevenue, Net (Deprecated 2018-01-31) 9 month as first filedRevenue, Net (Deprecated 2018-01-31) 12 monthRevenue, Net (Deprecated 2018-01-31) 12 month as first filed
2018-03-31$4.78M
10-Q · filed 2018-05-09
$5.98M
derived: sum of 2 quarters · filed 2018-05-09
$7.61M
derived: sum of 3 quarters · filed 2018-05-09
$8.32M
derived: sum of 4 quarters · filed 2018-05-09
2017-12-31$1.19M
10-K · filed 2018-03-15
$2.82M
derived: sum of 2 quarters · filed 2018-03-15
$3.54M
derived: sum of 3 quarters · filed 2018-03-15
$4.00M
10-K · filed 2018-03-15
2017-09-30$1.63M
10-K · filed 2018-03-15
$2.35M
derived: sum of 2 quarters · filed 2018-03-15
$2.81M
10-Q · filed 2017-11-09
$3.32M
derived: sum of 4 quarters · filed 2018-05-09
2017-06-30$718.00K
10-K · filed 2018-03-15
$1.18M
10-Q · filed 2017-08-11
$1.69M
derived: sum of 3 quarters · filed 2018-05-09
$2.63M
derived: sum of 4 quarters · filed 2018-05-09
2017-03-31$462.00K
10-Q · filed 2018-05-09
$971.00K
derived: sum of 2 quarters · filed 2018-05-09
$1.91M
derived: sum of 3 quarters · filed 2018-05-09
$3.02M
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31$509.00K
10-K · filed 2018-03-15
$1.45M
derived: sum of 2 quarters · filed 2018-03-15
$2.56M
derived: sum of 3 quarters · filed 2018-03-15
$3.48M
10-K · filed 2018-03-15
$3.34M
10-K · filed 2017-03-24
2016-09-30$936.00K
10-K · filed 2018-03-15
$889.00K
10-Q · filed 2016-10-26
$2.05M
derived: sum of 2 quarters · filed 2018-03-15
$2.97M
10-Q · filed 2017-11-09
$2.58M
10-Q · filed 2016-10-26
$3.63M
derived: sum of 4 quarters · filed 2018-03-15
2016-06-30$1.11M
10-K · filed 2018-03-15
$874.00K
10-Q · filed 2016-08-15
$2.03M
10-Q · filed 2017-08-11
$1.69M
10-Q · filed 2016-08-15
$2.69M
derived: sum of 3 quarters · filed 2018-03-15
$3.19M
derived: sum of 4 quarters · filed 2018-03-15
2016-03-31$917.00K
10-K · filed 2018-03-15
$818.00K
10-Q · filed 2016-05-16
$1.58M
derived: sum of 2 quarters · filed 2018-03-15
$2.08M
derived: sum of 3 quarters · filed 2018-03-15
$2.81M
derived: sum of 4 quarters · filed 2018-03-15
2015-12-31$659.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24
$1.16M
derived: sum of 2 quarters · filed 2017-03-24
$1.89M
derived: sum of 3 quarters · filed 2017-03-24
$2.54M
10-K · filed 2017-03-24
2015-09-30$501.00K
10-Q · filed 2016-10-26
$1.24M
derived: sum of 2 quarters · filed 2016-10-26
$1.88M
10-Q · filed 2016-10-26
$2.54M
derived: sum of 4 quarters · filed 2016-10-26
2015-06-30$734.00K
10-Q · filed 2016-08-15
$1.38M
10-Q · filed 2016-08-15
$2.03M
derived: sum of 3 quarters · filed 2016-08-15
$3.33M
derived: sum of 4 quarters · filed 2016-08-15
2015-03-31$645.00K
10-Q · filed 2016-05-16
$1.30M
derived: sum of 2 quarters · filed 2016-05-16
$2.60M
derived: sum of 3 quarters · filed 2016-05-16
$3.88M
derived: sum of 4 quarters · filed 2016-05-16
2014-12-31$655.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21
$1.96M
derived: sum of 2 quarters · filed 2016-03-21
$3.23M
derived: sum of 3 quarters · filed 2016-03-21
$4.32M
10-K · filed 2016-03-21
2014-09-30$1.30M
10-Q · filed 2015-11-13
$1.30M
10-Q · filed 2014-11-14
$2.58M
derived: sum of 2 quarters · filed 2015-11-13
$3.67M
10-Q · filed 2015-11-13
$3.67M
10-Q · filed 2014-11-14
$4.76M
derived: sum of 4 quarters · filed 2015-11-13
2014-06-30$1.27M
10-Q · filed 2015-08-14
$1.27M
10-Q · filed 2014-08-14
$2.36M
10-Q · filed 2015-08-14
$2.36M
10-Q · filed 2014-08-14
$3.46M
derived: sum of 3 quarters · filed 2015-08-14
$4.44M
derived: sum of 4 quarters · filed 2015-08-14
2014-03-31$1.09M
10-Q · filed 2015-05-15
$2.18M
derived: sum of 2 quarters · filed 2015-05-15
$3.16M
derived: sum of 3 quarters · filed 2015-05-15
$4.27M
derived: sum of 4 quarters · filed 2015-05-15
2013-12-31$1.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27
$2.07M
derived: sum of 2 quarters · filed 2015-03-27
$3.18M
derived: sum of 3 quarters · filed 2015-03-27
$4.32M
10-K · filed 2015-03-27
2013-09-30$983.59K
10-Q · filed 2014-11-14
$2.09M
derived: sum of 2 quarters · filed 2014-11-14
$3.23M
10-Q · filed 2014-11-14
2013-06-30$1.10M
10-Q · filed 2014-08-14
$2.24M
10-Q · filed 2014-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
uniQure N.V. (QURE)$2.416B-4.93
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Zai Lab Ltd (ZLAB)$2.241B-113.34
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03